Investor information
Company Overview
We are a global company specialized in precision diagnostic and treatment medical services, leaders in telediagnosis and oncology treatment. Our commitment is to transform healthcare by bringing personalized solutions closer to each of our clients and patients through technology, research, and expert knowledge.
Shareholder structure: shareholder structure as at 25 January 2022 with 61,389,673 shares in issue
- Free Float 37.6%
- Excelsior Times 30.5%
- Caser Group 5.2%
- Global Porfolio Investments 6.3%
- Equipo Directivo 9%
- Inveready VC 5.1%
- Onchena S.L. 6.2%
Share information:
2017
2018
2019
2020
2021
2022
No. of shares (thousands of shares)
11.153
20.430
22.695
33.596
61.390
73.643
P. at Period end
2,15
2,80
5,00
8,90
10,15
6,20
Maximum P.
2,15
3,32
6,05
9,00
11,25
10,85
Minimum P.
1,39
1,86
2,76
3,00
8,06
5,10
Market Capitalisation (EUR thousand)
23.979
57.205
113.475
299.005
623.105
456.587
Volume traded (thousands of shares)
260
772
3.798
7.099
11.185
6.714
Volume traded (EUR thousand)
1.071
10.339
19.961
48.501
104.467
48.011
Figures in thousands. Pro forma data including full year impact of acquisitions carried out. Source: BME
Analyst Reports
Rating Reports
Financial Results 2025
March 31 2026 at 10 am. CEST.
Extraordinary General Shareholders’ Meeting 2025
December 19, 2025 at 13 pm. CEST.
Would you like to get in touch with the Investor Relations department?
Tell us how we can help you